Laura MD - Sage Therapeutic Chief Officer
| SAGE Stock | USD 5.47 0.08 1.44% |
Executive
Laura MD is Chief Officer of Sage Therapeutic
| Age | 55 |
| Address | 215 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 299 8380 |
| Web | https://www.sagerx.com |
Sage Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.2962) % which means that it has lost $0.2962 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4934) %, meaning that it created substantial loss on money invested by shareholders. Sage Therapeutic's management efficiency ratios could be used to measure how well Sage Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.64. In addition to that, Return On Capital Employed is expected to decline to -0.76. At present, Sage Therapeutic's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 7.3 M, whereas Other Current Assets are forecasted to decline to about 21.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emil MD | Terns Pharmaceuticals | 44 | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Jim Watters | Relay Therapeutics | N/A | |
| Eric MD | Pliant Therapeutics | 60 | |
| Evan MBA | Alnylam Pharmaceuticals | N/A | |
| John Soglia | Nuvalent | N/A | |
| Paul McInulty | Arvinas | N/A | |
| Ronald Peck | Arvinas | N/A | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Pushkal MD | Alnylam Pharmaceuticals | 56 | |
| Ben Strain | Incyte | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 |
Sage Therapeutic Leadership Team
Elected by the shareholders, the Sage Therapeutic's board of directors comprises two types of representatives: Sage Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sage. The board's role is to monitor Sage Therapeutic's management team and ensure that shareholders' interests are well served. Sage Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sage Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jim Doherty, Chief Officer | ||
| Aaron MD, Medical Development | ||
| Christopher Benecchi, Chief Officer | ||
| Laura MD, Chief Officer | ||
| Heinrich Schlieker, Senior Operations | ||
| Albert Robichaud, Chief Scientific Officer | ||
| Anne Esq, General VP | ||
| Erin Lanciani, Vice President - Human Resources | ||
| Ashley Kaplowitz, Director Relations | ||
| Kimi CPA, CFO Treasurer | ||
| Helen Colquhoun, Senior Pharmacovigilance | ||
| Amy Schacterle, Vice President - Regulatory Affairs and Quality Assurance | ||
| Mike Quirk, Chief Officer | ||
| Pamela Herbster, VP People | ||
| Gregory Shiferman, Senior Counsel | ||
| Matt Lasmanis, Chief Officer | ||
| Barry Greene, CEO President | ||
| Helen Rubinstein, Investor Officer | ||
| Vanessa Procter, Senior Affairs |
Sage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sage Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (8.53) % | ||||
| Current Valuation | (224.26 M) | ||||
| Shares Outstanding | 61.17 M | ||||
| Shares Owned By Insiders | 11.91 % | ||||
| Shares Owned By Institutions | 86.43 % | ||||
| Number Of Shares Shorted | 6.41 M | ||||
| Price To Earning | 3.07 X | ||||
| Price To Book | 0.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.